Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.